Table 2:
Patient Characteristics by Degree of Neutropenia
| Mild (n=42) |
Moderate (n=34) |
Severe (n=25) |
p-value* | |
|---|---|---|---|---|
| Median time to neutropenia, months (IQR) | 4.9 (2.4–13.2) | 6.2 (3.4–27.2) | 3.8 (2.1–6.8) | 0.342 |
| Valcyte at time of Neutropenia, n(%) | 19 (45.2) | 16 (47.1) | 14 (56) | 0.680 |
| Calcineurin Inhibitor at Neutropenia | 0.181 | |||
| Tacrolimus | 41 (97.6) | 31 (91.2) | 25 (100) | |
| Cyclosporine | 1 (2.4) | 3 (.8) | 0 | |
| Prednisone Dose at time of Neutropenia, mg, median (IQR) | 7.5 (5–60) | 10 (5–35) | 10 (5–50) | 0.296 |
| Mycophenolate Dose at time of Neutropenia, g, Median (IQR) | 1 (0.5–2) | 1 (0.5–2) | 1 (0.5–2) | 0.826 |
| Mycophenolate Response to Neutropenia, n (%) | 0.141 | |||
| No Change | 12 (28.6) | 5 (14.7) | 5 (20) | |
| Dose Decrease | 6 (14.3) | 3 (8.8) | 2 (8) | |
| Dose Held | 24 (57.1) | 26 (76.5) | 16 (64) | |
| Medication Change | 0 | 0 | 2 (8) | |
| G-CSF Administered for Neutropenia, n(%) | 6 (14.3) | 9 (26.5) | 12 (48) | 0.011 |
| Duration of Neutropenia, days, median (IQR) | ||||
| GCSF Administered | 5 (1–7) | 7 (6–37) | 8 (4–11) | 0.026 |
| GCSF Not Administered | 9.5 (6–34.5) | 8 (5–28) | 8 (3–32) | 0.656 |
| p-value for Duration of Neutropenia^ | 0.023 | 0.274 | 0.956 |
*
Reported p-value is for comparison between neutropenia severity groups.
^
reported p-value is for comparison within each neutropenia severity group based on whether or not they received GCSF.